|
|
|
| Effect of resolving turbidity and removing toxicity comprehensive treatment on patients with stage 2-3 of chronic kidney disease |
| YAO Shuoshuo1 WEI Xiaona2 JI Dawei1 ZHENG Linlin1 FENG Cun2 |
1.Graduate School, Hebei University of Chinese Medicine, Hebei Province, Shijiazhuang 050000, China;
2.Department of Nephrology, Hebei Hospital of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Hebei Province, Shijiazhuang 050000, China |
|
|
|
Abstract Objective To observe the effect of resolving turbidity and removing toxicity comprehensive treatment on patients with stage 2-3 of chronic kidney disease (CKD). Methods A total of 160 patients with stage 2-3 of CKD in Nephrology Outpatient and Ward Department of Hebei Hospital of Traditional Chinese Medicine were selected from October 2017 to March 2019. Stratified by age, the patients were randomly divided into two groups, 78 cases in the treatment group and 82 cases in the control group. The treatment group was treated with resolving turbidity and removing toxicity comprehensive treatment plan, and the control group was treated with Niaoduqing Granules orally. Three months was a course of treatment. The overall efficacy, traditional Chinese medicine (TCM) syndrome score, renal function index (blood creatinine [Scr], blood urea nitrogen [BUN], uric acid [UA]), hemoglobin (HGB) and serum transforming growth factor-β1 (TGF-β1) levels before and after treatment were observed. Results The total effective rate in the treatment group was higher than that in the control group. After treatment, the TCM symptom score, Scr, BUN, and TGF-β1 levels were reduced in both groups, and the TCM symptom score, Scr, BUN, UA, and TGF-β1 levels in the treatment group were lower than those in the control group (P ＜ 0.05). After treatment, the HGB level was reduced in both groups, and the treatment group was higher than that in the control group (P ＜ 0.05). Conclusion Resolving turbidity and removing toxicity comprehensive treatment can regulate cytokines and effectively delay the progression of CKD.
|
|
|
|
|
|
[1] 王海燕.肾脏病学[M].3版.北京：人民卫生出版社，2008：1819.
[2] 吕曼曼，吕小林，陶菁.全程系统化干预对慢性肾衰竭患者疗效及治疗依从性的影响[J].解放军预防医学杂志，2019，37（11）：18-19.
[3] 韩龙，闵文，吴铭杰，等.补肾通络方促进骨质疏松症大鼠骨形成机制[J].中国中西医结合杂志，2019，39（1）：97-102.
[4] Kidney Disease: Improving Global Outcomes （KDIGO） CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis，Evaluation，Prevention，and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder（CKD-MBD）[J]. Kidney Int Suppl，2017，7（1）：1-59.
[5] 国家中医药管理局医政司.22个专业95个病种中医诊疗方案[M].北京：中国中医药出版社，2010：203-208.
[6] 李佃贵.浊毒论[M].北京：人民卫生出版社，2016：125-127.
[7] 邬墩彤，胡顺金.慢性肾脏病中晚期非透析患者中医证候分布规律探讨[J].中医药临床杂志，2020，32（1）：81-86.
[8] 夏娟娟，谭颖颖，黄笛，等.基于李东垣学术思想治疗慢性肾功能衰竭[J].中医学报，2020，35（2）：266-269.
[9] 石伟荣，吴强，魏仲南.魏仲南主任医师治疗慢性肾衰竭思路及临证经验初探[J].中国中西医结合杂志，2018，38（12）：1443-1247，1256.
[10] 王筝，刘文康，冯桃花，等.慢性肾脏病毒瘀相关病机探讨[J].河北中医，2019，41（12）：1893-1895，1920.
[11] 赵亚亚，钟成，李悦，等.TGF-β1介导的Smad通路在肾脏纤维化中的作用及机制[J].解放军预防医学杂志，2018，36（4）：427-430，458.
[12] 周珊珊，艾中柱，李伟男，等.大黄抗肾脏纤维化的网络药理学及其活性成分的作用机制[J].中国实验方剂学杂志，2020，10（2）：12-13.
[13] 阎磊，王丽姣，朱清，等.70例狼疮性肾炎患者肾脏纤维化及临床指标分析[J].中华实用诊断与治疗杂志，2020， 34（1）：40-43.
[14] 敖碧凤，罗兰，苏盛发，等.TGF-β1/Smads信号通路在放射性心肌纤维化中的作用[J].实用癌症杂志，2019， 34（1）：171-173.
[15] 张勇，张巍，张剑平，等.干细胞对环孢素肾病大鼠肾组织转化生长因子β1的影响[J].中华细胞与干细胞杂志：电子版，2017，7（1）：18-22.
[16] 沈金峰，胡芳，黄伟，等.从浊邪论治慢性肾脏病[J].中华中医药学刊，2019，10（25）：1-8.
[17] 牛莉，于泓苓.中药当归的化学成分分析与药理作用研究[J].中西医结合心血管病电子杂志，2018，6（21）：90-92.
[18] 张小鹿，谢光亮，周晨辰，等.川芎嗪对人间皮细胞水通道蛋白-1表达的影响[J].中国中西医结合肾病杂志，2019，20（9）：801-804.
[19] 盖晓红，刘素香，任涛，等.黄连的化学成分及药理作用研究进展[J].中草药，2018，49（20）：4919-4927.
[20] 范久梅，马卓.土茯苓药学研究概述[J].安徽农业科学，2018，46（8）：36-37，57.
[21] 冯冰，王乾，王园园.通腑泄浊法中药灌肠联合血液透析治疗慢性肾功能衰竭的临床观察[J].中华中医药学刊，2019，37（1）：180-182.
[22] 许梦白，秦雪，肖翔，等.结肠透析联合中药保留灌肠治疗慢性肾衰竭临床研究[J].实用中医药杂志，2018，34（4）：459-460. |
|
|
|
